Efficacy and safety of antibody-drug conjugates in EGFR-mutant non-small cell lung cancer after tyrosine kinase inhibitor resistance: a systematic review and meta-analysis - Takeaways - MDSpire

Efficacy and safety of antibody-drug conjugates in EGFR-mutant non-small cell lung cancer after tyrosine kinase inhibitor resistance: a systematic review and meta-analysis

  • By

  • Xiao Ma

  • Gaofeng Li

  • Heng Li

  • July 16, 2026

Share

  • 1

    The systematic review included nine studies with 1,092 patients evaluating antibody-drug conjugates in EGFR-mutant NSCLC after TKI failure.

  • 2

    The pooled objective response rate for ADCs was 44.7%, with significant heterogeneity based on the target antigen.

  • 3

    TROP2-targeting ADCs showed a higher objective response rate of 50.6% compared to HER3-targeting ADCs at 34.2%.

  • 4

    Sacituzumab tirumotecan demonstrated improved progression-free survival and overall survival compared to chemotherapy.

  • 5

    The findings indicate that ADC efficacy is target- and drug-specific, highlighting the need for biomarker-guided patient selection.

Original Source(s)

Efficacy and safety of antibody-drug conjugates in EGFR-mutant non-small cell lung cancer after tyrosine kinase inhibitor resistance: a systematic review and meta-analysis

  • by Xiao Ma, Gaofeng Li, Heng Li

  • July 16, 2026

Related Content

GLA is associated with ESCC progression and chemotherapy response via DNA damage repair–related pathways

Errors in Abstract

  • July 15, 2026

Mass Spec Roundup: Signals Recovered

This week’s stories span amino-metabolite imaging, site-specific HDX-MS, large-scale motif annotation, and proteomics missing-value recovery

  • July 15, 2026

  • 7 min